Drug Approval | November 03, 2022
Glenmark receives ANDA approval for Sodium Phenylbutyrate Tablets
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
Subscribe To Our Newsletter & Stay Updated
